KBE Building Corporation is a full-service commercial construction company founded in Connecticut with its home office in Farmington. KBE is strategically positioned to serve the Eastern, Mid-Atlantic, and Western U.S. through its regional offices in Connecticut, Arizona, and Maryland.

KBE is one of the KBE Companies, which includes KBE-NY, serving clients in metropolitan New York, and New Valley Construction, which works with select clients throughout the US.

With its 200+ preconstruction and construction staff, KBE provides preconstruction, construction management, design-build, and general contracting services to clients  in the senior living, educational, retail, health care, federal, corporate, hospitality & entertainment, and institutional markets.

KBE has the expertise to serve the biotech and life sciences industries through its work for higher education and other research-based institutions where it has created the physical environments that support research and development.

In 2022, KBE launched the KBE Foundation (kbefoundation.org) to formalize the firm’s long tradition of community support. www.kbefoundation.org

OmniCyte is a preclinical stage, immunology based, biotechnology company located in Branford Connecticut. The company was founded with a focus on developing targeted treatments to address significant unmet medical needs. Our therapeutics are developed from our proprietary Targeted Immune Activation, platform technology. The platform consists of a bi-specific protein complex, with a conserved domain that activates an immune response through the dendritic cell, and a variable targeting domain that can be engineered to target numerous tumor types and pathogens. OmniCyte boasts a strong management team and an even stronger bench of advisors & collaborators.

Hamilton Robotics is a global leader in liquid handling and laboratory automation technology, advancing the laboratory analytical sciences through reliability, performance, and flexibility. For more than 70 years, Hamilton has exceeded expectations. The measure of excellence.

In 2022, Apple Tree Partners formed ATP R&D Labs as an in-house incubator and accelerator to drive the foundational science for ATP portfolio companies and spark the beginnings of future ventures.  ATP R&D Labs state-of-the-art facility in New Haven, Connecticut, offers a full suite of services in compound screening, cellular and molecular assays, data analytics, and preclinical pharmacology.

ATP R&D employs in vivo and in vitro methodologies to discover and evaluate small molecules, working closely with ATP’s team of business and scientific experts, senior leaders at ATP portfolio companies, and scientific founders and partners.

Matchbook specializes in providing flexible procurement/strategic sourcing services to fast-growing Biotech and Life Science firms. Ranging from CPO strategic insight to tactical execution, we optimize your capital while ensuring you are building a scalable, sustainable, and risk-adverse supply chain. Whether analyzing supplier spend – outlining short- and long-term cost efficiencies; or working with your Category stakeholders to map out timelines to needs, alerting them to spend consolidations or avoidances; we aim to support, not supplant, your procurement team.

All-in, we work to make our client’s budgets last longer and protect your company’s bandwidth by leveraging our wide breadth of procurement experience and category knowledge. Our services can be for short or long-term solutions while your company grows. We can slow your cash burn, and lengthen your financial runway to Commercialization or Product Launch.

Catailyst has combined automation and artificial intelligence to understand scientific, clinical and business announcements from various public information sources, such as press releases, SEC filings, and trial registrations to create actionable and searchable data points. Catailyst has recently launched a database and data analytics platform to provide access to such data. The company has also developed several real-time alerts.

Catailyst aims to provide this data to its customers from a cloud based platform with SAAS (software as a service) subscription business model. The company brings a comprehensive solution for Biotech and Pharma business development teams, clinical development team, investment bankers, investors, and life science consultants to track drug development, monitor competition, follow market trends and inform about recent developments of drug candidates and approved drugs.

Catailyst has developed many proprietary methods of artificial intelligence involving machine learning and natural language processing methods to read and analyze different forms of texts announced daily such as press releases, SEC filings and trial registrations. Catailyst was in stealth for the last three years and during this time the company has developed several methods of artificial intelligence. A patent related to such invention was filed to USPTO in 2020 and the company filed PCT applications in certain countries from EU, Canada and India. No patents have been granted.

Catailyst has added business process automation to its artificial intelligence and enabled methods of identifying, extracting and categorizing relevant data points without human intervention. By implementing such a process, the Company processes 500+ press releases, 100+ clinical trials related information, and hundreds of SEC filings everyday.

Quinnipiac is a private, coeducational university where students engage in an educational experience that’s both personal and challenging from faculty who care deeply about student outcomes. We offer 150 programs to approximately 7,000 undergraduate and 3,000 graduate students.
We are building the University of the Future at Quinnipiac. We are a community enriched by our ideas, inclusive excellence and commitment to preparing graduates as enlightened global citizens equipped for the challenges and opportunities of 21st-century careers.

At Modifi Bio, we are changing the oncology treatment paradigm.

Bypassing the conventional approach of indirectly targeting proteins in cancer cells,
Modifi Bio is redefining the rules of oncology treatment: eradicating cancer via direct
DNA modification. Our novel platform demonstrates powerful anti-tumor activity in
glioma and many other cancers with intrinsic DNA repair defects.

By developing therapeutics that uniquely target specific acquired cancer cell DNA
mutations, we’ll improve the standard of cancer therapy and patient care.

RIGImmune is a platform preclinical biopharmaceutical startup that was founded in early 2020 out of
Yale University. We are developing a new class of therapeutic oligonucleotides called stem loop
RNAs (SLRs) that work by selectively activating a protein called retinoic acid inducible gene I (RIG-I).
RIG-I acts a surveillance system recognizing common molecular features of RNA viruses, and when
activated triggers the innate immune response.

RIGImmune’s lead compound RIG-101 has demonstrated preclinical efficacy, tolerability, and proof
of principle in multiple viral respiratory disease and oncology models. The company is pursuing IND
enabling activities for RIG-101 for use as an influenza treatment.

In 2022 the company announced acquisition of Subintro, a complementary biotech working to
develop antiviral therapeutics for respiratory RNA viruses. The acquisition provided RIGImmune
access to the company’s novel intranasal delivery formulations and expertise to drive its intranasal
broad spectrum antiviral program forward.

RIGImmune was awarded a Grant from the Bill and Melinda Gates Foundation through their Global
Influenza Challenge Project to study the use of our compounds as effective therapeutics against
influenza and to demonstrate the adjuvant potential of RIG-101 when co-administered or co-
formulated with the influenza vaccine. In addition to grant funding, RIGImmune has raised funds
from a series seed round of financing, an additional equity investment through the Gates Foundation
Strategic Investments Fund, and through investment from F prime Capital accompanying the
acquisition of its formulation company.

TriNet partners with SMB’s to ensure compliance, reduce employer liability, sponsor large-group
robust healthcare insurance, and automate through an all-in-one platform. We work with Life Science
companies throughout the US who have 3-1000 employees.